Potential Link To Kidney Failure Observed in Invokana Lawsuit Plaintiffs using Diabetes Type-2 Drug

April 20, 2016 – – TheProductLawyers.com comments on released reports which demonstrate the potential link between new-generation diabetes drug, Invokana and serious renal impairment.

Within the first year of the drug being on the market, 50 adverse event reports were made by patients using the drug to the U.S. Food and Drug Administration.

FDA approval to treat type-2 diabetes patients using Invokana was obtained in 2013 and the drug was subsequently released to the market. Invokana acts to assist patients in managing their blood sugar (glucose) levels. Consequently, Invokana stops the kidneys from reabsorbing extra sugar in the body, by causing the kidneys to remove the extra blood sugar via urination. Invokana was released to market as the first of a group of drugs known as SGLT2 inhibitors. This abbreviation stands for sodium-glucose cotransporter-2.

As the action of Invokana results in excess kidney involvement, there is a greater potential risk to impose stress and damage upon the kidneys. Patients with diabetes are inherently prone to adverse renal events and those with pre-existing kidney impairment may be at increased risk of suffering additional damage to these important and complex organs.

The U.S. Food and Drug Administration issued a public safety warning on December 4, 2015, requiring important label warning adjustments for Invokana. The responsibility for making such changes lay with Invokana manufacturer Janssen Pharmaceuticals, which is a division of well-known Johnson & Johnson corporation. Concerned at this time, the FDA noted that they had received 19 adverse event reports from patients who claimed to have developed life-threatening complications after starting the drug.

It is alleged such concerning complications initially manifested as urinary tract infections (UTIs) which then progressed to become acute and dangerous blood and kidney infections. Filed reports indicated that each of the 19 patients discussed required emergency hospitalization and renal dialysis, a treatment for kidney failure. Damage to kidneys cannot be reversed. Consequently, kidney transplants are required for patients who have sustained substantial kidney damage.

For more information about the Invokana lawsuits, or this press release, please contact TheProductLawyers.com on 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60009436